{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:10:31Z","timestamp":1775279431550,"version":"3.50.1"},"reference-count":34,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.25087","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:12:47Z","timestamp":1774908767000},"page":"27-36","source":"Crossref","is-referenced-by-count":0,"title":["CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency\/dysregulation among rheumatoid arthritis patients treated with methotrexate"],"prefix":"10.3960","volume":"66","author":[{"given":"Keisuke","family":"Sawada","sequence":"first","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Oral Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Fukumura","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Onagi","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Saitama Red Cross Hospital, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kashimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shinmatsudo Central General Hospital, Chiba, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018; 320: 1360-1372.","DOI":"10.1001\/jama.2018.13103"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fraenkel L, Bathon JM, England BR <i>et al.<\/i> 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021; 73: 1108-1123.","DOI":"10.1002\/art.41752"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Salloum E, Cooper DL, Howe G <i>et al.<\/i> Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996; 14: 1943-1949.","DOI":"10.1200\/JCO.1996.14.6.1943"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hoshida Y, Tsujii A, Ohshima S <i>et al.<\/i> Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis\u2013Associated Lymphoproliferative Disorders. Arthritis Rheumatol. 2024; 76: 869-881.","DOI":"10.1002\/art.42809"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Alaggio R, Amador C, Anagnostopoulos I, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hasserjian RP, Chen S, Perkins SL <i>et al.<\/i> Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol. 2009; 22: 1532-1540.","DOI":"10.1038\/modpathol.2009.131"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tokuhira M, Saito S, Okuyama A <i>et al.<\/i> Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018; 59: 1143-1152.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Sawada K, Momose S, Iijima Y <i>et al.<\/i> EBV-positive mucocutaneous ulcer arising in methotrexate-treated rheumatoid arthritis patients: a clinicopathological study of 12 cases with analysis of PD-L1 expression. J Clin Exp Hematop. 2023; 63: 90-98.","DOI":"10.3960\/jslrt.22048"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kamel OW, van de Rijn M, Weiss LM <i>et al.<\/i> Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993; 328: 1317-1321.","DOI":"10.1056\/NEJM199305063281806"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Miyazaki T, Fujimaki K, Shirasugi Y <i>et al.<\/i> Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007; 82: 1106-1109.","DOI":"10.1002\/ajh.21003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Momose S, Tamaru J-I. Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting. J Clin Exp Hematop. 2019; 59: 48-55.","DOI":"10.3960\/jslrt.19014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kurita D, Miyoshi H, Ichikawa A <i>et al.<\/i> Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. Am J Surg Pathol. 2019; 43: 869-884.","DOI":"10.1097\/PAS.0000000000001271"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Shiraiwa S, Kikuti YY, Carreras J <i>et al.<\/i> Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions. J Clin Exp Hematop. 2020; 60: 159-168.","DOI":"10.3960\/jslrt.20041"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Takahashi T, Sawada K, Yamashita T <i>et al.<\/i> Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV+ DLBCL. Cancer Sci. 2025; 116: 2306-2316.","DOI":"10.1111\/cas.70111"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Hans CP, Weisenburger DD, Greiner TC <i>et al.<\/i> Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Mengel M, Loupy A, Haas M <i>et al.<\/i> Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation\u2013Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant. 2020; 20: 2305-2317.","DOI":"10.1111\/ajt.16059"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Dudziak D, Kieser A, Dirmeier U <i>et al.<\/i> Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-\u03baB signaling pathway. J Virol. 2003; 77: 8290-8298.","DOI":"10.1128\/JVI.77.15.8290-8298.2003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Ngo VN, Young RM, Schmitz R <i>et al.<\/i> Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470: 115-119.","DOI":"10.1038\/nature09671"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kim Y, Ju H, Kim DH <i>et al.<\/i> CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Hum Pathol. 2014; 45: 556-564.","DOI":"10.1016\/j.humpath.2013.10.023"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Nihira K, Ando Y, Yamaguchi T <i>et al.<\/i> Pim-1 controls NF-\u03baB signaling by stabilizing RelA\/p65. Cell Death Differ. 2010; 17: 689-698.","DOI":"10.1038\/cdd.2009.174"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gonzalez-Farre B, Ramis-Zaldivar JE, de Anta NC <i>et al.<\/i> Intravascular large B-cell lymphoma genomic profile is characterized by alterations in genes regulating NF-\u03baB and immune checkpoints. Am J Surg Pathol. 2023; 47: 202-211.","DOI":"10.1097\/PAS.0000000000001978"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Inui Y, Matsuoka H, Yakushijin K <i>et al.<\/i> Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015; 56: 3045-3051.","DOI":"10.3109\/10428194.2015.1022769"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford). 2017; 56: 940-946.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 995-1007.","DOI":"10.1200\/JCO.2005.02.4786"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Urata T, Naoi Y, Jiang A <i>et al.<\/i> Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study. Blood Adv. 2023; 7: 7459-7470.","DOI":"10.1182\/bloodadvances.2023010402"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hock BD, Haring LF, Steinkasserer A <i>et al.<\/i> The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res. 2004; 28: 237-241.","DOI":"10.1016\/S0145-2126(03)00255-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Hock BD, Fernyhough LJ, Gough SM <i>et al.<\/i> Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res. 2009; 33: 1089-1095.","DOI":"10.1016\/j.leukres.2009.01.001"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Li Z, Ju X, Lee K <i>et al.<\/i> CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018; 103: 655-665.","DOI":"10.3324\/haematol.2017.178384"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Horvatinovich JM, Grogan EW, Norris M <i>et al.<\/i> Soluble CD83 inhibits T cell activation by binding to the TLR4\/MD-2 complex on CD14+ monocytes. J Immunol. 2017; 198: 2286-2301.","DOI":"10.4049\/jimmunol.1600802"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 S\u00e9n\u00e9chal B, Boruchov AM, Reagan JL, Hart DNJ, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood. 2004; 103: 4207-4215.","DOI":"10.1182\/blood-2003-12-4350"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Lechmann M, Krooshoop DJ, Dudziak D <i>et al.<\/i> The extracellular domain of CD83 inhibits dendritic cell\u2013mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med. 2001; 194: 1813-1821.","DOI":"10.1084\/jem.194.12.1813"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol. 2005; 174: 6672-6676.","DOI":"10.4049\/jimmunol.174.11.6672"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Baleeiro R, Barbuto JAM. Local secretion\/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism. Mol Immunol. 2008; 45: 3502-3504.","DOI":"10.1016\/j.molimm.2008.04.005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Saito S, Suzuki K, Yoshimoto K <i>et al.<\/i> Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol. 2018; 9: 621.","DOI":"10.3389\/fimmu.2018.00621"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25087\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:31:32Z","timestamp":1775277092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25087\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25087","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25087"}}